Cetera Advisor Networks’s BioNTech BNTX Stock Holding History

Cetera Advisor Networks’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-908	Closed	-$234K	–	2078
2021 Q4	$234K	Sell	908 -166	-15%	-$45.5K	﹤0.01%	1772
2021 Q3	$293K	Buy	+1,074	New	+$341K	﹤0.01%	1537
2020 Q3	–	Sell	-100	Closed	-$7K	–	1431
2020 Q2	$7K	Buy	+100	New	+$4.99K	﹤0.01%	2841

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $21.4B AUM 8.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cetera Advisor Networks's BNTX Position: Q1 2022 in Review

Cetera Advisor Networks sold out of BioNTech (BNTX) in Q1 2022, closing a stake of 908 shares — an estimated $234K sold.

Cetera Advisor Networks first reported a position in BNTX in Q2 2020 and held it in 3 quarters. The position peaked at $293K in Q3 2021. 287 funds tracked by Wall St. Rank hold BNTX as of Q1 2022.

Cetera Advisor Networks reported no remaining BioNTech position as of Q1 2022 after selling out during the quarter.
Cetera Advisor Networks sold 908 BioNTech shares in Q1 2022, an estimated $234K.
Cetera Advisor Networks first reported a position in BioNTech in Q2 2020 and held it in 3 quarters.
Cetera Advisor Networks's BioNTech position peaked at $293K in Q3 2021.
287 funds tracked by Wall St. Rank held BioNTech as of Q1 2022.

Based on Cetera Advisor Networks's 13F filing for Q1 2022, filed 12 May 2022.